BioCryst Pharmaceuticals | BCRX - Ebitda


BioCryst Pharmaceuticals reported $51.7M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Chugai Pharma JPY 193.44B 23.07B Sep/2026
Daiichi Sankyo JPY 116.06B 14.46B Jun/2026
DBV Technologies USD -61.2M 15.3M Sep/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Glaxosmithkline GBP 2.93B 154M Sep/2026
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Neurocrine Biosciences USD 375.3M 185.4M Sep/2026
Novavax USD 19.36M 190.79M Dec/2025
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026